Is there data supporting dual checkpoint inhibitor immunotherapy combined with platinum‑based chemotherapy for advanced non‑small‑cell lung cancer lacking targetable EGFR (epidermal growth factor receptor) or ALK (anaplastic lymphoma kinase) alterations in patients with ECOG (Eastern Cooperative Oncology Group) performance status 0‑1?

Yes, there is strong data supporting dual checkpoint inhibitor immunotherapy combined with chemotherapy in advanced NSCLC without driver alterations.

For patients with EGFR/ALK-negative advanced NSCLC and ECOG PS 0-1, nivolumab plus ipilimumab combined with two cycles of platinum-based chemotherapy is a guideline-supported treatment option, particularly for those with PD-L1 <1% or 1-49% expression. 1

Evidence Quality and Strength

The CheckMate 9LA trial provides the most robust evidence for dual immunotherapy with chemotherapy:

• 4-year survival data demonstrated a 34% reduction in death risk for patients with PD-L1 <1% (HR 0.66,95% CI 0.50-0.86) 1
• In nonsquamous NSCLC, the benefit was more modest but significant (4-year OS rate: 22% vs 19%; HR 0.80,95% CI 0.66-0.97) 1
• The regimen uses only two cycles of platinum-based chemotherapy combined with ongoing nivolumab/ipilimumab, reducing chemotherapy exposure 1

The CheckMate 227 trial (dual immunotherapy without chemotherapy) showed:

• 6-year sustained survival benefit (HR 0.65,95% CI 0.52-0.81) 1
• However, this was in patients with PD-L1 ≥1% and high tumor mutational burden (TMB) 2

Guideline Recommendations by PD-L1 Status

PD-L1 1-49%:

• Should offer: Pembrolizumab + carboplatin + paclitaxel (or cemiplimab combination) 1
• May offer: Nivolumab + ipilimumab + 2 cycles platinum chemotherapy 1
• May offer: Durvalumab + tremelimumab + platinum chemotherapy 1

PD-L1 <1%:

• Should offer: Pembrolizumab + carboplatin + paclitaxel (or cemiplimab combination) 1
• May offer: Nivolumab + ipilimumab + 2 cycles platinum chemotherapy 1
• May offer: Durvalumab + tremelimumab + platinum chemotherapy 1

Important Caveats

Toxicity considerations:

• CheckMate 9LA: 57% serious adverse events in overall population, 2% fatal AEs 1
• CheckMate 227: 33% grade ≥3 toxicity with dual immunotherapy, 18% treatment discontinuation vs 9% with chemotherapy 1
• POSEIDON trial: 51.8% grade ≥3 toxicity with durvalumab/tremelimumab/chemotherapy vs 44.4% with chemotherapy alone 1

Strength of recommendations:

• The ASCO 2024 guideline rates these dual immunotherapy + chemotherapy combinations as "may offer" (weak recommendation) rather than "should offer" due to modest OS benefits in some subgroups and increased toxicity 1, 3
• Single-agent pembrolizumab + chemotherapy remains the preferred standard with stronger recommendation strength 1, 3

Clinical Decision Algorithm

For PD-L1 ≥50%: Single-agent pembrolizumab is preferred; dual immunotherapy + chemotherapy is not the standard approach 1, 3

For PD-L1 1-49% or <1%:

1. First choice: Pembrolizumab (or cemiplimab) + platinum + pemetrexed (nonsquamous) or paclitaxel (squamous) 1
2. Alternative if high TMB available: Consider nivolumab + ipilimumab ± 2 cycles chemotherapy 2
3. Consider dual ICI + chemotherapy if: Patient can tolerate increased toxicity risk and you want to minimize chemotherapy cycles (only 2 cycles vs 4-6) 1

Avoid in:

• Squamous histology with contraindications to immunotherapy
• ECOG PS >1
• Active autoimmune disease or significant immunosuppression 2

The data supports dual immunotherapy with chemotherapy as a viable option, but it is not universally superior to single checkpoint inhibitor + chemotherapy combinations, which remain the preferred standard in most guidelines.